GlassScriptPhysician profile
Mari M Batta
NPI 1184891871
$1,151.57
in general payments reported to CMS, 2019-2025
12 companies · $161 in 2025
The $161 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $27.21 · 2021: $30.32 · 2022: $89.55 · 2023: $140 · 2024: $342 · 2025: $161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $643.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $339.70 | 2019-2023 | Adbry |
| Genzyme Corporation | $170.64 | 2024 | |
| Abbvie INC. | $123.89 | 2022-2025 | Skyrizi |
| Regeneron Healthcare Solutions, INC. | $115.58 | 2019-2025 | Libtayo |
| E.R. Squibb & Sons, L.L.C. | $102.42 | 2024 | Sotyktu |
| Janssen Biotech, INC. | $86.80 | 2020-2025 | Tremfya |
| Conmed Corporation | $49.87 | 2023 | Visiclear |
| Arcutis Biotherapeutics, INC. | $48.33 | 2023-2024 | Zoryve |
| Botanix Sb INC | $47.35 | 2025 | Sofdra |
| Sun Pharmaceutical Industries INC. | $39.29 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $14.90 | 2020 | |
| Galderma Laboratories, L.P. | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mari Batta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.